Summer Sale! Get unlimited digital access for 13 weeks for $13.
Business
Business

Emergent BioSolutions strikes $222M deal to buy Cangene Corp.

Rockville biotechnology company Emergent BioSolutions Inc. has struck a deal to buy Canadian firm Cangene Corp., which employs 100 people in Baltimore, for $222 million in cash, the companies said Thursday.

Emergent is paying $3.24 per share for Cangene, gaining its products used in biodefense as well as its manufacturing capabilities. Cangene operates a contract manufacturing facility in the Carroll-Camden Industrial area along the Russell Street corridor.

Emergent develops, manufactures and sells products used in defense and commercial markets, including treatments to prevent anthrax disease and remove or neutralize chemical warfare agents from skin.

The combined company expects annual revenue of $436 million, Emergent said in a news release.

The deal is subject to a two-thirds vote by Cangene shareholders as well as approval by a Canadian court. It is expected to close in early 2014.

sdance@baltsun.com

twitter.com/ssdance

Copyright © 2015, The Baltimore Sun
Related Content
  • Rockville firm lands contract for government anthrax vaccines

    Emergent BioSolutions Inc. of Rockville said Monday it won a five-year contract worth up to $1.25 billion to provide millions of doses of an anthrax vaccine for government stockpiles.

  • Baltimore People on the Move archive

    Baltimore People on the Move archive

    Readers submit photos and information on employees who have recently been promoted, hired or honored at area businesses. Select photos will be published in the Maryland Business section of Tuesday editions of The Baltimore Sun. Caption size is limited and only photos are accepted in this feature....

Comments
Loading
79°